Class summary at a glance.

Every drug in the Endothelin Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $2.33Bcombined across class
Total Rx claims: 258K38K unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Macitentan

Brand: OPSUMIT · 146K Part D claims (CY24) · 21K beneficiaries · First FDA approval: 2013-11-04

5 generic mfrs 252 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.87B

Class share

80%

of class CY24 spend

View profile →

Ambrisentan

Brand: Letairis · 98K Part D claims (CY24) · 15K beneficiaries · First FDA approval: 2007-06-15

8 generic mfrs 562 plans require PA

Low NADAC$8.34

→

Avg plan cost$8.34

Part D spend $364.6M 1× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Sparsentan

Brand: FILSPARI · 4K Part D claims (CY24) · 767 beneficiaries · First FDA approval: 2023-02-17

Brand-only (no generics) 64 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $48.4M

Class share

of class CY24 spend

View profile →

Bosentan

Brand: Tracleer · 10K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2001-11-20

4 generic mfrs 685 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $48.1M

Class share

of class CY24 spend

View profile →

Aprocitentan

Brand: TRYVIO · 67 Part D claims (CY24) · 30 beneficiaries · First FDA approval: 2024-03-20

Brand-only (no generics) 5 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $77158

Class share

of class CY24 spend

View profile →

Macitentan and Tadalafil

Brand: OPSYNVI · — Part D claims (CY24) · First FDA approval: 2024-03-22

Brand-only (no generics) 62 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.